Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    reprise II

Performance and Safety of the Lotus™ Valve With a FLEXible Delivery System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03043404
Recruitment Status : Completed
First Posted : February 6, 2017
Last Update Posted : July 5, 2019
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To confirm the acute performance and safety of the Lotus™ Valve Flex System for transcatheter aortic valve replacement (TAVR) in symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Device: Transcatheter aortic valve replacement Not Applicable

Detailed Description:
This clinical study is a prospective, single-arm study designed to confirm that the acute performance and safety of the Lotus Valve Flex System for TAVR are consistent with the results of the Lotus Valve System in the REPRISE II study, when delivered and deployed in symptomatic subjects who have severe calcific aortic valve stenosis and who are at high risk for surgical aortic valve replacement (SAVR).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: REPRISE II FLEX: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With a FLEXible Delivery System - Confirmation of Performance and Safety
Actual Study Start Date : December 3, 2013
Actual Primary Completion Date : December 10, 2013
Actual Study Completion Date : December 10, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lotus Valve Flex System
Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
Device: Transcatheter aortic valve replacement
TAVR with Lotus Valve Flex System




Primary Outcome Measures :
  1. Technical success [ Time Frame: immediately post-procedure ]
    defined as successful vascular access, delivery and deployment of the Lotus Valve and successful retrieval of the delivery system; and correct positioning of a single Lotus Valve in the proper anatomical location; reported as percent of subjects.


Secondary Outcome Measures :
  1. Mean aortic valve pressure gradient and effective orifice area [ Time Frame: at discharge or 7 days post-procedure (whichever comes first) ]
    as measured by echocardiography and assessed by an independent core laboratory

  2. Device performance [ Time Frame: at discharge or 7 days post-procedure (whichever comes first) ]
    defined as successful repositioning of the Lotus Valve if repositioning is attempted; and successful retrieval of the Lotus Valve if retrieval is attempted; and grade of paravalvular aortic regurgitation, as measured by echocardiography and assessed by an independent core laboratory


Other Outcome Measures:
  1. Mortality: all-cause, cardiovascular, and non-cardiovascular [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  2. Stroke: disabling and non-disabling [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  3. Composite of all-cause mortality and disabling stroke [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  4. Bleeding: life-threatening (or disabling) and major [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  5. Myocardial infarction (MI) [ Time Frame: periprocedural (≤72 hours post index procedure) and spontaneous (>72 hours post index procedure) ]
  6. Acute kidney injury: based on the AKIN System Stage 3 (including renal replacement therapy) or Stage 2 [ Time Frame: ≤7 days post index procedure ]
  7. Major vascular complication [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  8. Repeat procedure for valve-related dysfunction (surgical or interventional therapy) [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  9. Hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV) [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  10. New permanent pacemaker implantation resulting from new or worsened conduction disturbances (including new left bundle branch block [LBBB] and third degree atrioventricular block) [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  11. New onset of atrial fibrillation or atrial flutter [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  12. Coronary obstruction [ Time Frame: ≤7 days post procedure ]
  13. Ventricular septal perforation, reported as percent of subjects [ Time Frame: ≤7 days post procedure ]
  14. Mitral apparatus damage, reported as percent of subjects [ Time Frame: ≤7 days post procedure ]
  15. Cardiac tamponade, reported as percent of subjects [ Time Frame: ≤7 days post procedure ]
  16. Prosthetic aortic valve malposition, including valve migration, valve embolization, ectopic valve deployment, or transcatheter aortic valve (TAV)-in-TAV deployment [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  17. Prosthetic aortic valve thrombosis [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  18. Prosthetic aortic valve endocarditis [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
  19. Prosthetic aortic valve performance [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
    as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory, including effective orifice area, mean and peak aortic gradients, peak aortic velocity, and grade of aortic regurgitation

  20. Functional status [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
    as evaluated by the New York Heart Association (NYHA) classification

  21. Neurological status [ Time Frame: at discharge and 1 year ]
    as determined by the National Institutes of Health Stroke Scale (NIHSS)

  22. Neurological status [ Time Frame: at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 months, and 1, 2, 3, 4, and 5 years post procedure ]
    as determined by the Modified Rankin Scale (mRS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   70 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Subject is ≥70 years of age
  • 2. Subject has documented calcific native aortic valve stenosis with an initial aortic valve area (AVA) of <1.0 cm2 (or AVA index of <0.6 cm2/m2) and either a mean pressure gradient >40 mm Hg or a jet velocity >4 m/s, as measured by echocardiography
  • 3. Subject has a documented aortic annulus size between ≥20 and ≤27 mm based on pre-procedure diagnostic imaging
  • 4. Symptomatic aortic valve stenosis with NYHA Functional Class ≥ II
  • 5. Subject is considered high risk for surgical valve replacement based on at least one of the following:

    1. Society of Thoracic Surgeons (STS) score ≥8%, AND/OR
    2. Agreement by the heart team (which must include an in-person evaluation by an experienced cardiac surgeon) that subject is at high operative risk of serious morbidity or mortality with surgical valve replacement
  • 6. Heart team (which must include an experienced cardiac surgeon) assessment that the subject is likely to benefit from valve replacement.
  • 7. Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent.
  • 8. Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits.

Exclusion Criteria:

  1. Subject has a congenital unicuspid or bicuspid aortic valve.
  2. Subject with an acute myocardial infarction within 30 days of the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation).
  3. Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months, or has any permanent neurologic defect prior to study enrollment.
  4. Subject is on dialysis or has serum creatinine level >3.0 mg/dL or 265 µmol/L.
  5. Subject has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic ring in any position.
  6. Subject has ≥3+ mitral regurgitation, ≥3+ aortic regurgitation or ≥3+ tricuspid regurgitation (i.e., subject cannot have more than moderate mitral, aortic or tricuspid regurgitation).
  7. Subject has a need for emergency surgery for any reason.
  8. Subject has a history of endocarditis within 12 months of index procedure or evidence of an active systemic infection or sepsis.
  9. Subject has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.
  10. Subject has Hgb <9 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3.
  11. Subject requires chronic anticoagulation therapy (warfarin) and cannot tolerate concomitant therapy with either aspirin or clopidogrel.

    Note: Subjects who require chronic anticoagulation must be able to be treated additionally with either aspirin or clopidogrel. An alternative P2Y12 inhibitor may be prescribed if subject is allergic to or intolerant of clopidogrel.

  12. Subject has active peptic ulcer disease or gastrointestinal bleed within the past 3 months, other bleeding diathesis or coagulopathy or will refuse transfusions.
  13. Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin, nickel, tantalum, titanium, or polyurethanes.
  14. Subject has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrollment.
  15. Subject has hypertrophic obstructive cardiomyopathy.
  16. Subject has any therapeutic invasive cardiac procedure (including balloon aortic valvuloplasty) within 30 days prior to the index procedure (except for pacemaker implantation which is allowed).
  17. Subject has untreated coronary artery disease, which in the opinion of the treating physician is clinically significant and requires revascularization.
  18. Subject has documented left ventricular ejection fraction <30%.
  19. Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices.
  20. Subject has severe peripheral vascular disease (including aneurysm defined as maximal luminal diameter >5 cm or with documented presence of thrombus, marked tortuosity, narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick [>5 mm], protruding or ulcerated atheroma in the aortic arch) or symptomatic carotid or vertebral disease.
  21. Femoral artery lumen of <6.0 mm for subjects requiring 23 mm valve size or <6.5 mm for subjects requiring 27 mm valve size, or severe iliofemoral tortuosity or calcification that would prevent safe placement of the introducer sheath.
  22. Current problems with substance abuse (e.g., alcohol, etc.).
  23. Subject is participating in another investigational drug or device study that has not reached its primary endpoint.
  24. Subject has untreated conduction system disorder (e.g., Type II second degree atrioventricular block) that in the opinion of the treating physician is clinically significant and requires a pacemaker implantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03043404


Locations
Layout table for location information
Australia, Queensland
Prince Charles Hospital
Chermside, Queensland, Australia, 4032
Australia, Victoria
Monash Heart
Clayton, Victoria, Australia, 3168
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Principal Investigator: Ian T Meredith, MD, PhD Monash
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT03043404    
Other Study ID Numbers: S2321
First Posted: February 6, 2017    Key Record Dates
Last Update Posted: July 5, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction